Dublin, Jan. 12, 2018 -- The "Allergic Rhinitis Forecast in 26 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.
This report provides the current prevalent population for allergic rhinitis across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Finland, Denmark, Austria, Portugal, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight, several features of allergic rhinitis patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of allergic rhinitis include:
- Asthma
- Conjunctivitis
- Chronic otitis media with effusion
- Eustachian tube dysfunction
- Sleep impairment
- Obstructive sleep apnoea
- Rhinosinusitis
- Pollen-food cross-reactivity
- Laryngeal irritation
- Globus sensation
Reasons to Buy:
- Ability to quantify patient populations in global allergic rhinitis market to target the development of future products, pricing strategies and launch plans.
- Further insight into the prevalence of the subdivided types of allergic rhinitis and identification of patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Better understanding of the impact of specific co-morbid conditions on the prevalent population of allergic rhinitis patients.
- Identification of allergic rhinitis patient sub-populations that require treatment.
- Better understanding of the specific markets that have the largest number of allergic rhinitis patients.
Key Topics Covered:
- Introduction
- Cause of the Disease
- Risk Factors & Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis & Clinical Course
- Key Comorbid Conditions / Features Associated With the Disease
- Methodology for Quantification of Patient Numbers
- Top-Line Prevalence for Allergic Rhinitis
- Features of Allergic Rhinitis Patients
- Treatment of Allergic Rhinitis Patients
- Comorbidities of Allergic Rhinitis Patients
- Abbreviations Used in the Report
- Other Services & Solutions
- Reports & Publications
- Online Epidemiology Databases
- Online Pharmaceutical Pricing Database
- References
- Appendix
For more information about this report visit https://www.researchandmarkets.com/research/vb3rjn/allergic_rhinitis?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Allergy Drugs


Anta Sports Expands Global Footprint With Strategic Puma Stake
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 



